Physician profile
Caleb E Wheeler
NPI 1962528984
$1,017.50
in general payments reported to CMS, 2019-2025
25 companies · $277 in 2025
The $277 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $75.19 · 2023: $94.30 · 2024: $213 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $113.88 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $107.79 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $86.16 | 2019-2025 | |
| Neos Therapeutics, Lp | $79.14 | 2019-2023 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $75.43 | 2024-2025 | Qelbree |
| Corium, LLC | $68.43 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $60.68 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $56.95 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $43.61 | 2024 | Strensiq |
| Seqirus USA INC | $40.87 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $34.59 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $32.85 | 2024-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Prugen, INC. Pharmaceuticals | $28.81 | 2019 | |
| Roche Diagnostics Corporation | $20.03 | 2019 | |
| Genzyme Corporation | $18.85 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $18.81 | 2024 | |
| Collegium Pharmaceutical, INC. | $18.15 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $15.80 | 2019 | |
| Cipher Pharmaceuticals US LLC | $15.55 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.29 | 2019 | |
| Aytu Biopharma, INC. | $13.67 | 2024 | Karbinal |
| Lnhc, INC | $13.46 | 2025 | Zelsuvmi |
| Organon LLC | $13.00 | 2025 | Vtama |
| Genentech USA, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.